Navigation Links
ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Date:12/11/2007

ignificant unmet need.

Prevention and Treatment of Venous Thromboembolic disease (VTE)

Venous thromboembolic disease (deep vein thrombosis (DVT), pulmonary embolism) represents a major health issue, with an incidence of 1 to 3 per 1000 individuals per year and a high early mortality rate. One of the risk factors for VTE is major orthopaedic surgery. Anticoagulation prophylaxis is therefore indicated in this setting. In addition, in patients who develop a VTE, anticoagulation treatment for at least 6 months is indicated. Therefore, an agent allowing for once-a-month treatment in an outpatient setting is foreseen as an important option for the treatment of VTE.

Stroke Prevention in Atrial Fibrillation (AF)

Atrial fibrillation (AF), which is a strong risk factor for ischemic stroke, is the most common sustained arrhythmia observed in clinical practice. The prevalence of AF is estimated at 0.4% of the general population and increases with age, rising to 8.8% in the group aged 80-89 years. Given the aging population in the U.S. and other developed countries, the overall prevalence of AF is expected to continue to grow over the next several decades.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular and eye diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which is expected to proceed to Phase I clinical trials by the end of 2007. ThromboGenics has built strong links with the University of Leuven
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
7. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
9. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
10. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
11. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2008)... money on home medical and wellness .... 15 /- VidaCura, Incorporated,today...lness store,VidaCura.com. VidaCura.com provides a...ess products along with information and insurance,...ove their health and,learn how they can manage med...
(Date:10/15/2008)... and business development flexibility, TSX Exchan...tCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RV...lion or approximately 60% of its remaining USD$17.... and CEO of Resverlogix stated, "The,economic envi...companies,around the globe. This action limits our...
(Date:10/15/2008)...ael, October 15 /-,Simbionix USA Corp... Series,C round of growth capital financing led by...investor Early Stage Partners and other existing,s...ho served as the,company,s investment bankers. The...e already rapid growth of its medical simulation t...
(Date:10/15/2008)...e-FirstCall/ -- Cryo-Cell,International, Inc. (OTC...,world,s largest and most established family cord ... quarter and nine months ended August 31,2008., ...pproximately $4.5,million compared to approximatel...Company reported a net loss in the third quarter 2...
Breaking Biology Technology:In the Midst of International Economic Crisis, VidaCura Offers a Helping Hand to Those Without Insurance 2Resverlogix Eliminates Sixty Percent of Remaining Debt 2Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth 2Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth 3Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 2Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 3Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 4Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 5Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 6
...San Diego - A company that uses Medical College o...logical expertise has been awarded $2.5 million fo...nia. , ,The company, Nanogen, Inc., said the res...ars, would enable it to develop improved molecular...d demonstrate the performance of this new molecula...
... Madison, Wis. - It,s not surprising that Gov. J...ill at odds over how the state,s latest budget wil...Doyle thinks he saved K-12 districts from cuts wit...yle abused his veto power and put more spending on...r public education appears destined never to be se...
...MILWAUKEE -- Marshall & Ilsley Corp . announced ...th Plansmith Corp . of Schaumburg, Ill., to expan... ,With the partnership, M&I will use Plansmith,s C...ware to assist financial institutions in their pro...,M&I began offering a planning assistance program ...
... An entry to a consumer,s house in any foreign lan...re was this product born? What,s its true national...today? What,s the bearer,s nation done for my nati...o secret that consumers all over the world are far...o. They clearly support or oppose their own countr...
Other Biology Technology:Before deciding how to pay for K-12 schools, let's determine what to buy 2Before deciding how to pay for K-12 schools, let's determine what to buy 3Why are brands culturally profiled? 2Why are brands culturally profiled? 3
(Date:10/14/2008)..., The gecko,s amazing ability to stick to surfaces...o manufacture materials that mimic the special sur...o,s ability to stick so well is a forest of pillar... gecko,s foot. Because there are so many pillars s...face the gecko is walking on by a molecular force ...
(Date:10/14/2008)... Infection is the leading cause of infant deaths ...ker, pre-term infants. Current diagnostic tests ca...ow identified potential biomarkers in the blood th...n and type of microbe. , The circulatory system...tephen Kingsmore and colleagues analyzed plasma sa...
(Date:10/14/2008)...tics researchers have identified two novel gene lo... they continue to reveal pieces of the complicated...expect to improve predictive tests and devise prev... of the biology of type 1 diabetes and better unde...ill be able to develop better diagnostic tests tha...
(Date:10/14/2008)...ADELPHIAThe National Institutes of Health has awar...an scientists, including The Academy of Natural Sc...nd biofuels technology from marine mollusks for de...concentrated in the Philippine archipelago, whose ... mollusk speciesabout a fifth of all the known spe...
Breaking Biology News(10 mins):Researchers continue to find genes for type 1 diabetes 2Academy participates in project to discover drugs, biofuels in tropical seas 2Perr 26Knight Announces Discounted Fee Schedule for Access to Its Online Database of Commercial Lines Competitor Filings 17456 1Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous 28TM 29 Bio engineered R stent 28TM 29 17452 1Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous 28TM 29 Bio engineered R stent 28TM 29 17452 2Orchard Supply Hardware Partners With Canary Foundation 17448 1Orchard Supply Hardware Partners With Canary Foundation 17448 2Orchard Supply Hardware Partners With Canary Foundation 17448 3Elusys Anthim 28TM 29 Dramatically Improves Survival of Animals Treated After Active Anthrax Infection 4776 1Elusys Anthim 28TM 29 Dramatically Improves Survival of Animals Treated After Active Anthrax Infection 4776 2Elusys Anthim 28TM 29 Dramatically Improves Survival of Animals Treated After Active Anthrax Infection 4776 3
...ngton University in St. Louis have made an importa...ells take to silence unwanted or extra genes using...ossible to see where, and how, the events in the p...ving, as the old saying goes. , Craig Pikaa...ogy in Arts & Sciences and his collaborators h...
...lose oneself" in an experience? Many theoretical m...at awareness is dependent on the mediation of area...f-aware "observer" network ?in the human brain. , ...el of the Weizmann Institute,s Neurobiology Depart...uestion ?by scanning the brains of volunteers perf...
...f bacteria -- the way they get a foothold in plant...cording to research published this week by Michiga...he bacterial pathogen Pseudomonas syringae, better...e pathogen reared its speckled head in tomatoes, c...describes using P. syringae in the laboratory plan...
... that dynamic regions of the human genome -- "hots...e potentially involved in the rapid evolution of m...re genetically determined. , Now, an international... and an associate professor from Arizona State Uni...es, which has implications for the understanding o...
Other Biology News:Pathway toward gene silencing described in plants 2Pathway toward gene silencing described in plants 3Pathway toward gene silencing described in plants 4Lost in thought: Brain research 2Chimpanzee study reveals genome variation hotspots 2
...le rapid analytical to medium scale affinity purif...opriate vectors. Sufficient reagents are provided ...r native or denaturing conditions. Crude samples a...cally retains STag fusion proteins. After unbound ...
Request Info
...10 ,Yeast extract, 5 ,Sodium chloride, 10 ,A...0.5 ,IPTG, 0.03 ,-Gal is a patented, water so...actosidase. The enzymatic hydrolysis of S-Gal by -...ate. Lac+ colonies grown in the presence of S-gal ...
Physical form: Lyophilized powder containing Tris buffer salts Preparation Unit Definition: One unit will convert 1.0μmole of 2-phosphoglycerate to phospho(enol)pyruvate per min at pH7.4 at 25 C
Biology Products: